Blend Hopes To Improve Upon Performance Of Antibody-Drug Conjugates
This article was originally published in The Pink Sheet Daily
Executive Summary
While its most advanced program is a prodrug of cisplatin designed to enter tumors as they absorb albumin, Blend is particularly excited about Pentarins, its novel class of conjugated cancer therapeutics.
You may also be interested in...
Forest Buys Clinical Data And Extends Its Antidepressant Portfolio
The Lexapro maker will pay $1.2 billion upfront plus potential milestones to gain a recently approved antidepressant Viibryd.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.